You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 44 No. 7, July 1987 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  NEUROLOGICAL REVIEWS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (96)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Thrombolysis and Stroke

Past and Future

Michael A. Sloan, MD

Arch Neurol. 1987;44(7):748-768.


Abstract



• Investigators have tried to limit ischemic cerebral infarct size by pharmacologic and surgical means with mixed results. Thrombolytic (fibrinolytic) therapy has been used in the past with unfavorable outcome. With advances in clinical and radiologic assessment and new knowledge of the pathophysiology of brain ischemia, thrombolytic therapy has now become a feasible pharmacologic intervention in acute stroke. Central nervous system hemorrhage, the most dread complication of fibrinolytic therapy, is rare in patients with acute myocardial infarction favorably treated with these agents. Risk of hemorrhagic transformation of ischemic cerebral infarcts is related to size, location, and age of patient. Anticoagulation therapy may increase its size, but not its likelihood. The development of clot-specific agents, such as tissue-type plasminogen activator, and careful patient selection make fibrinolytic therapy safe and potentially effective in acute stroke.



Author Affiliations



From the Department of Neurology, Tufts New England Medical Center, Boston. Dr Sloan is now with the Department of Neurology, University of Virginia Medical Center, Charlottesville.


Footnotes



Accepted for publication March 5, 1987.

Reprint requests to Department of Neurology, University of Virginia Medical Center, Box 394, Charlottesville, VA 22908 (Dr Sloan).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Future of Acute Stroke Treatment: Lessons We Have Learned From Laboratory and Clinical Research
Frey
Arch Intern Med 1995;155:1005-1006.
ABSTRACT  

Streptokinase in the Treatment of an Acute Cerebral Embolus A Case Report
Frink and Ostrach
ANGIOLOGY 1990;41:66-69.
ABSTRACT  

Ruptured Arteriovenous Malformation Complicating Thrombolytic Therapy With Tissue Plasminogen Activator
Proner et al.
Arch Neurol 1990;47:105-106.
ABSTRACT  

Treatment for Stroke
Gilson
ANN INTERN MED 1989;111:1048-1049.
ABSTRACT  

Acute Cerebral Ischemia in a Critical Care Unit: A Review of Diagnosis and Management
Levine
Arch Intern Med 1989;149:90-98.
ABSTRACT  

Intracerebral Hemorrhage Complicating Intravenous Tissue Plasminogen Activator Treatment
Carlson et al.
Arch Neurol 1988;45:1070-1073.
ABSTRACT  

Tissue Plasminogen Activator: Reduction of Neurologic Damage After Experimental Embolic Stroke
Zivin et al.
Arch Neurol 1988;45:387-391.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.